EcoDrugPlus

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSLCAG00010009932
Gene Symbol: GRM4
1 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSLCAG00010010829
Gene Symbol: GRM4
1 Cross references
196 Possible Orthologues:

Glutamate Receptor 2

Ensembl ID : ENSLCAG00010007982
Gene Symbol: LOC108900100
4 Cross references
242 Possible Orthologues:

Glutamate Receptor 3

Ensembl ID : ENSLCAG00010024948
Gene Symbol: LOC108893426
4 Cross references
251 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSLCAG00010022791
Gene Symbol: LOC108879165
4 Cross references
249 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSLCAG00010005799
Gene Symbol: GRIA1A
1 Cross references
251 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSLCAG00010022371
Gene Symbol: GRIA2B
4 Cross references
224 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 1a

Ensembl ID : ENSLCAG00010022690
Gene Symbol: GRIN1A
4 Cross references
205 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a, B

Ensembl ID : ENSLCAG00010007104
Gene Symbol: GRIN2AB
3 Cross references
98 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSLCAG00010025912
Gene Symbol: GRIN2BB
1 Cross references
250 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2d, A

Ensembl ID : ENSLCAG00010024543
Gene Symbol: LOC108886961
2 Cross references
214 Possible Orthologues:

Glutamate Receptor, Metabotropic 2b

Ensembl ID : ENSLCAG00010008999
Gene Symbol: GRM2B
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).